Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| EP-129 | Human | TSLP[Biotinylated]:IL-7Rα & TSLP R Inhibitor Screening ELISA Kit | |||
| ILR-H525x | Human | Human IL-7 R alpha&TSLP R Heterodimer Protein, Fc Tag&Fc Tag |  |
|
|
| CHEK-ATF045 | Human | Human TSLP R (Luc) HEK293 Reporter Cell | |||
| ILR-H5255 | Human | Human IL-7 R alpha&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (MALS verified) |  |
|
|
Co-expression analysis of human TSLP R and IL-7 R alpha on Human TSLP R (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human TSLP R (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-TSLP R antibody and FITC-labeled anti-IL-7 R alpha antibody.
Loaded Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H525x) on Protein A Biosensor, can bind Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) with an affinity constant of 1.16 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H5255) on Protein A Biosensor, can bind Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) with an affinity constant of 134 pM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| PF-06342674 | RN-168; PF-6342674; PF-06342674 | Pfizer Inc | Details | ||
| MDK-703 | MDK-703 | Phase 1 Clinical | Medikine Inc | Details | |
| ASP-9801 | ASP-9801 | Phase 1 Clinical | Astellas Pharma Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| Lusvertikimab | OSE-127; S-95011 | Phase 2 Clinical | Effimune | Sjogren's Syndrome; Colitis, Ulcerative | Details |
| Interleukin-7 (Revimmune SAS) | rhIL-7; CYT-107; CYT-99-007 | Phase 2 Clinical | Cytheris | Urinary Bladder Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Melanoma; Catheter-Related Infections; T-Lymphocytopenia, Idiopathic CD4-Positive; Leukemia, Myeloid, Acute; Hepatitis C; Ureteral Neoplasms; Urologic Neoplasms; Lymphopenia; Neuroblastoma; Sarcoma; Urethral Neoplasms; Prostatic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Carcinoma, Transitional Cell; Coronavirus Disease 2019 (COVID-19); Mycobacterium Infections, Nontuberculous; Sepsis; Myeloproliferative Disorders; Myelodysplastic Syndromes; Hepatitis B, Chronic; Carcinoma, Renal Cell; Rhabdoid Tumor; Shock, Septic; Kidney Neoplasms; HIV Infections | Details |
| Efineptakin alfa | NT-I7; GX-I7; TJ-107 | Phase 2 Clinical | Genexine Inc | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Sarcoma, Kaposi; Carcinoma, Squamous Cell; Leukoencephalopathy, Progressive Multifocal; Gliosarcoma; Astrocytoma; Lymphopenia; Colorectal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; HIV Infections; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Coronavirus Disease 2019 (COVID-19); Papillomavirus Infections; Glioblastoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Esophageal Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
